血浆H3.1核小体作为感染、炎症和器官衰竭的生物标志物
本研究利用MARS队列,纳入1713例连续ICU患者,在第0、2、4天采集血浆,用Nu.Q® NETs免疫分析法测定H3.1核小体浓度。结果显示,临床裁定确诊脓毒症者基线H3.1为740 ng/mL,未确诊脓毒症者为416 ng/mL,非脓毒症者为463 ng/mL(P < 0.001);H3.1与SOFA评分相关(r = 0.40),在弥散性血管内凝血、急性肾损伤和高炎症性脓毒症患者中更高。H3.1对肾脏替代治疗需求有高度预测性(每log10升高风险比2.00,校正死亡后)。结论认为脓毒症和器官衰竭与血浆H3.1核小体浓度密切相关,但个体诊断性能低。
要点
- 在1713例ICU患者中,确诊脓毒症者基线H3.1核小体浓度为740 ng/mL,未确诊脓毒症者为416 ng/mL,非脓毒症者为463 ng/mL(P < 0.001)。
- H3.1核小体浓度与SOFA评分相关(r = 0.40),并在弥散性血管内凝血、急性肾损伤和高炎症性脓毒症患者中更高。
- H3.1核小体浓度对肾脏替代治疗需求有高度预测性,每log10升高风险比2.00(校正死亡后)。
- H3.1核小体对脓毒症和器官衰竭的个体诊断性能低,但可预测肾脏替代治疗和弥散性血管内凝血需求。
适用人群与场景
- 连续纳入的ICU重症患者(MARS队列)。
研究设计与关键结果
- 研究类型为队列研究(MARS队列),纳入1713例连续ICU患者,共3671份血浆样本,在第0、2、4天采集。
- 基线H3.1核小体浓度:临床裁定确诊脓毒症740 ng/mL,未确诊脓毒症416 ng/mL,非脓毒症463 ng/mL(P < 0.001)。
- H3.1浓度与SOFA评分相关(r = 0.40),在弥散性血管内凝血、急性肾损伤和高炎症性脓毒症患者中更高。
- H3.1浓度对肾脏替代治疗需求高度预测,每log10升高风险比2.00(校正死亡后)。
- H3.1对脓毒症和器官衰竭的个体诊断性能低。
证据类型、等级与局限
- 证据类型:队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论认为脓毒症和器官衰竭与血浆H3.1核小体浓度密切相关,但个体诊断性能低;H3.1水平可预测肾脏替代治疗和弥散性血管内凝血需求。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Neutrophil extracellular traps (NETs) are a vital part of the innate immune response, while excessive NET formation can cause tissue damage. H3.1 nucleosomes, a component of NETs, have emerged as a potential biomarker. This study aimed to evaluate H3.1 nucleosomes in critical illness, assessing their relationship with sepsis, organ failure, inflammatory subphenotypes and outcomes.
METHODS: The MARS cohort was used, comprising of consecutive Intensive Care Unit patients, with plasma samples collected on days 0, 2 and 4. H3.1 nucleosome concentrations were measured using the Nu.Q® NETs Immunoassay. H3.1 nucleosome concentrations were compared across sepsis presence and organ failure, both at baseline and longitudinally. The relationship between H3.1 nucleosome concentrations and clinical outcomes was investigated.
RESULTS: 1713 critically ill patients were included, with a total of 3671 plasma samples. Baseline H3.1 nucleosome concentrations differed between sepsis confirmed by clinical adjudication (740 ng/mL), sepsis unconfirmed by clinical adjudication (416 ng/mL) and non-sepsis (463 ng/mL, P < 0.001). H3.1 concentrations were associated with SOFA score (r = 0.40) and were higher in patients with disseminated intravascular coagulation, acute kidney injury and hyperinflammatory sepsis. H3.1 concentration was highly predictive for the need of renal replacement therapy (hazard ratio 2.00 per log10 increase), correcting for mortality.
CONCLUSIONS: Sepsis and organ failure were closely associated with plasma H3.1 nucleosome concentrations. While individual diagnostic performance for sepsis and organ failure remained low, H3.1 levels predicted the need for renal replacement therapy and disseminated intravascular coagulation, revealing unique insights into the innate immune response.
TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT01905033; IRB number 10-056C, registered June 16, 2010.
参考来源
- Filippini DFL, Jiang M, Kramer L, et al. Plasma H3.1 nucleosomes as biomarkers of infection, inflammation and organ failure. Crit Care. 2025. PMID: 40390092. doi:10.1186/s13054-025-05415-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。